Overall, the analysis supports improved MDM2 antagonist clinical outcomes in AML patients with higher levels of MDM2 protein expression and thus, MDM2 protein expression from blasts may serve as a stratification biomarker for AML patients likely to benefit from idasanutlin-based therapy [114]. The gene discussed is MDM2; the disease is acute myeloid leukemia.